Vaxxinity developed a vaccine to train the immune system to attack only abnormal forms of alpha synuclein, aiming to help the body treat itself by recognizing personal misfolded proteins.
A new diagnostic test for Parkinson's, using cerebrospinal fluid to measure abnormal alpha synuclein levels, is awaiting FDA approval, potentially being the first test for the disease.
The research targets abnormal alpha synuclein, a protein implicated in Parkinson's, offering hope for improved diagnostics and treatments in a disease lacking effective options.
#parkinsons-disease #diagnostic-test #immune-based-treatment #alpha-synuclein-protein #medical-research
Collection
[
|
...
]